Tetsuro Taki

10PUBLICATIONS
127CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsiesMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 30, 2026
Neoadjuvant olaparib and pembrolizumab combination therapy in the treatment of patients with HRD-positive advanced ovarian cancer: A pilot study.

|Apr 29, 2025
The Lung Cancer Autochthonous Model Gene Expression Database Enables Cross-Study Comparisons of the Transcriptomic Landscapes Across Mouse Models.

Ling Cai, Fangjiang Wu, Qinbo Zhou

|Nov 18, 2024
NETosis in pulmonary pleomorphic carcinoma.

Hajime Oi, Tetsuro Taki, Takashi Kuroe

|Oct 25, 2024
Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY).

Keiju Aokage, Shohei Koyama, Shogo Kumagai

|Sep 03, 2024
A novel histopathological feature of spatial tumor-stroma distribution predicts lung squamous cell carcinoma prognosis.

Tetsuro Taki, Yutaro Koike, Masahiro Adachi

|Mar 08, 2024
Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer.

Yusuke Nagasaki, Tetsuro Taki, Kotaro Nomura

Pageof 2

Frequent Collaborators

4 joint publications

Genichiro Ishii

3 joint publications

Shinji Mii

2 joint publications

Atsushi Enomoto

2 joint publications

Naoya Sakamoto